PACS Group Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board elections, auditor ratification, and executive compensation approval. All proposals passed, with final vote results to be published in a Form 8-K. No questions were submitted by stockholders.
-
Q1 2026 saw 11% revenue growth and a 75% rise in Adjusted EBITDA, driven by strong occupancy, skilled mix, and operational execution. Full-year Adjusted EBITDA guidance was raised by $50 million, with robust liquidity and a new $250 million share repurchase plan.
-
The organization reported record growth in 2025, driven by a mission-focused model, high occupancy, and strong financials. Despite ongoing government investigations, leadership emphasized operational strength, robust M&A opportunities, and optimistic guidance for 2026.
-
The group detailed its mission-driven, decentralized approach to post-acute care, emphasizing growth through acquisition and operational turnaround of underperforming facilities. Strong financials, a robust M&A pipeline, and a focus on higher acuity patients position it for continued expansion and innovation, with AI as a future differentiator.
Fiscal Year 2025
-
Record 2025 results driven by strong integration, occupancy, and clinical quality, with revenue up 29% and adjusted EBITDA reaching $505M. 2026 guidance targets 8% revenue and 12% EBITDA growth, supported by disciplined acquisitions and a robust pipeline.
-
Record revenue and adjusted EBITDA were achieved in Q3 and year-to-date 2025, driven by strong operational execution, portfolio expansion, and high occupancy rates. Full-year 2025 guidance projects 30% revenue growth and record adjusted EBITDA, with disciplined capital allocation and a focus on quality care.
Fiscal Year 2024
-
Q2 2024 saw 29.1% revenue growth and 53.8% higher adjusted EBITDA year-over-year, driven by high occupancy, strong clinical quality, and robust acquisitions. Updated 2024 guidance projects 25% revenue growth and continued margin expansion.